With the immuno-oncology space a battleground for large pharmaceutical companies, surely there isn't much a small biotech can offer? iTeos Therapeutics, a 2011 spin off from Ludwig Cancer Research, believes otherwise, CEO and founder Michel Detheux told Scrip.
"We're targeting hot and cold tumors," he explained. "This concept in targeting the tumor microenvironment is becoming more and more...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
